The Role of Apolipoprotein ApoC1 in Human Malignancies

Apolipoprotein C1 (ApoC1) is best known for its role in lipid metabolism, concerning cardiovascular risk factors and regarding similarities to apolipoprotein E, such as in Alzheimer’s disease.

Less common are publications describing the immunosuppressive effect of ApoC1 on macrophage activity, which can alter the immune response to infections or tumors. Since ApoC1 is expressed during macrophage activation, measuring ApoC1 serum levels may offer a possibility to monitor the course of an infection or of tumor growth.

This Special Issue aims to present the currently available body of knowledge concerning the potential use of ApoC1 as serum biomarker for human malignant disease.

Dear Colleagues,

With this Special Issue of MDPI Biology, we plan to focus on the role of ApoC1 in malignant disease.

On one hand, this role could be a passive one, with ApoC1 being expressed by activated macrophages, but it can also be active, through ApoC1 suppressing antitumoral immune response. Expression of ApoC1 by tumor tissue has also been described, potentially enabling tumor cells to interfere with the immune response, or meaning a significant part of the tumor contains activated macrophages. Secreted ApoC1 can be measured in blood serum, but it remains to be shown whether serum levels correlate to tumor burden or stage.

The scope of this issue covers research from “bench to bedside”. We invite basic genetic research on DNA level or mRNA expression, as well as proteomic technical abstracts on protein detection, histological papers, and especially clinical examinations or observations.

The purpose is to shed a light on ApoC1 in malignancies and to allow for an estimation of whether ApoC1 is a general bystander protein in most cancers or is restricted to certain entities. The overview of basic techniques in combination with clinical data then should allow for the development of biomarkers or even therapeutic approaches.

Several labs have in the past successfully performed research in this direction, so this Special Issue is set up to compile their most recent data, and to blend into the existing literature as a comprehensive overview. The implementation of research results derived from lipid metabolism and cardiovascular disease or Alzheimer’s disease will enlarge our knowledge and add to the existing literature.

We look forward to receiving your submissions supporting our project.

Prof. Dr. Ulf Nestler
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ApoC1 
• Biomarker 
• Cancer 
• Human 
• Macrophage 
• Serum